Company intelligence / Profile preview

UroGen Pharma

Princeton, New Jersey, USAurogen.com ↗

Ownership: Public · URGN
Employees: ~201
Development stage: Commercial

Overview

UroGen’s lead product, Jelmyto® (mitomycin) for pyelocalyceal solution, was approved by the FDA in 2020 as the first non-surgical therapy for LG‑UTUC. The company’s second lead asset, UGN‑102, has shown an 80.6% duration of response at 18 months in Phase 3 ENVISION trial data for recurrent LG IR-NMIBC and has a rolling NDA submission underway with potential FDA decision expected as early as Q1 2025[3][7]. Other programs are advancing through clinical development.

Therapeutic areas: Oncology
Modalities: small molecules (notably mitomycin)hydrogel-based drug delivery
Industry: Biotech

Drug pipeline

6 assets

zusduri

Approved

5 more assets in the full pipeline.

Request access →

Partnerships

medac GmbH (next-gen mitomycin formulations)[9]Pharmakon Advisors LP (financing partnership)[7]

Financials

Market cap: $2.1B
Total revenue: $72.5M
Enterprise value: $2.1B

Beyond the preview

Go deeper on UroGen Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on UroGen Pharma.

Explore the full profile